CN Menu
Press Release
Dr. Tom Du and Dr. Charles Lee attended the Hong Kong International Biotechnology Forum and deliver keynote speeches
Source:Evergreen Therapeutics Date: Sep,2023 Views: 206

On September 13th, the four-day BIOHK2023 Hong Kong International Biotechnology Forum kicked off at the Hong Kong Convention and Exhibition Center, Supported by the China Association for Science and Technology, the Ministry of Science and Technology, and the Hong Kong Special Administrative Region Government. BIOHK2023 stands as a preeminent international biotechnology event initiated by the esteemed Hong Kong Biotechnology Association, boasting its status as one of Asia's largest conferences in this field. This gathering convenes numerous distinguished experts and academicians across diverse disciplines, including Nobel laureate Dr. Bruce Beutler, Academician Gao Fu from Chinese Academy of Sciences, Academician Han Jisheng, Dr. Wang Yu from former National Center for Disease Control and Prevention, alongside various international medical policy makers, industry elites, academia representatives, and investment professionals to deliberate upon research accomplishments in different domains while fostering professional growth through innovative thinking exchange and successful experience sharing. Dr. Du Tao, Chairman of Evergreen Therapeutics, and Dr. Li Changqing, Chief Medical Officer were invited to attend this conference as guest speakers.

 

The conference theme, "Biotech Kaleidoscope," aims to explore the boundless possibilities of biopharmaceuticals through cutting-edge technologies. As an international event, the discussion surrounding the successful entry of Chinese innovative drugs into the global market remains highly significant. Dr. Du Tao, a seasoned FDA evaluation expert with extensive experience in technology transfer, delivered a keynote speech titled "Overseas Transfer Strategies for Chinese Innovative Drugs." Dr. Du emphasized that license-out has become an indispensable fourth capability in China's current strategy for expanding overseas markets for innovative drugs, and selecting appropriate clinical indications based on global clinical needs is crucial for achieving success. Accelerating the utilization of new technologies such as AI to enhance development efficiency and obtaining endorsement from international regulatory authorities can further augment the likelihood of successful expansion into foreign markets. During the subsequent panel discussion, Dr. Du shared his insights and experiences with experts, receiving unanimous recognition from attendees at the event.